OSRX Vows to Fight Back After $34.9 Million Trademark Verdict Favors ImprimisRx in Heated Legal Battle
MISSOULA, Mont. — OSRX, Inc., based in Missoula, Montana, recently conveyed its profound dissatisfaction with a jury verdict that found it and its associate company, Ocular Science, Inc., liable for willful trademark infringement and unfair competition, resulting in a substantial penalty of $34.9 million in damages. The lawsuit, initiated by ImprimisRx, a subsidiary of Harrow Health, Inc., was adjudicated in the Southern District of California. Throughout the proceedings, OSRX defended its use of certain abbreviations commonly utilized in ophthalmology, such as “Pred,” “Moxi,” “Dex,” and “Brom,” which refer to prednisolone, moxifloxacin, dexamethasone, and bromfenac, respectively. … Read more